Suppr超能文献

基于可溶性白细胞介素1受体样分子1水平探讨汤剂对慢性心力衰竭患者的心脏保护作用。

The cardioprotective effect of decoction on patients with chronic heart failure based on the levels of soluble interleukin 1 receptor-like 1.

作者信息

Zhang Lei, Ning Bing-Bing, Ma Si-Jia, Wang Lu-Ling, Wang Jing, Zhu Dan, Zhu Wen, Xie Feng-Qun, Cheng Jie, Feng Qi-Mao

机构信息

Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shang hai, 200071, China.

Department of Xin-Bing, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shang hai, 200071, China.

出版信息

Heliyon. 2023 Aug 19;9(9):e19294. doi: 10.1016/j.heliyon.2023.e19294. eCollection 2023 Sep.

Abstract

OBJECTIVE

The purpose of this study was to evaluate the protective effect of decoction on patients with chronic heart failure (CHF) based on the levels of soluble interleukin 1 receptor-like 1 (ST2).

METHODS

We included a total of 80 outpatients and inpatients with CHF who were undergoing treatment at the Shanghai Municipal Hospital of Traditional Chinese Medicine between March 2020 and March 2022. We randomly divided them into the observation group ( = 40) and the control group ( = 40). Patients in the control group received treatments as per conventional Western medicine, while those in the observation group were treated with the decoction in conjunction with Western medicine for eight consecutive weeks. We then compared the pre- and post-treatment levels of ST2 and N-terminal pro-brain natriuretic peptide (NT-proBNP) of the patients in the two groups.

RESULTS

There were no significant differences in the pre-treatment levels of ST2 and NT-proBNP indexes between the two groups ( > 0.05), while the post-treatment comparison between the two groups in terms of ST2 and NT-proBNP levels suggested that the effect in the observation group was better, with statistical significance ( < 0.05).

CONCLUSION

decoction was beneficial in patients with CHF, suggesting that it could be a promising and effective method for the treatment of CHF.

摘要

目的

本研究旨在基于可溶性白细胞介素1受体样1(ST2)水平评估[具体方剂名称]汤剂对慢性心力衰竭(CHF)患者的保护作用。

方法

纳入2020年3月至2022年3月期间在上海市中医医院接受治疗的80例CHF门诊及住院患者。将他们随机分为观察组(n = 40)和对照组(n = 40)。对照组患者接受常规西医治疗,而观察组患者连续8周接受[具体方剂名称]汤剂联合西医治疗。然后比较两组患者治疗前后的ST2和N末端脑钠肽前体(NT-proBNP)水平。

结果

两组患者治疗前ST2和NT-proBNP指标水平无显著差异(P > 0.05),而两组治疗后ST2和NT-proBNP水平比较显示观察组效果更好,具有统计学意义(P < 0.05)。

结论

[具体方剂名称]汤剂对CHF患者有益,表明其可能是一种有前景且有效的CHF治疗方法。

相似文献

6
[Zhenwu Decoction delays ventricular hypertrophy in rats with uremic cardiomyopathy].[真武汤延缓尿毒症性心肌病大鼠心室肥厚]
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Jan 30;39(1):113-119. doi: 10.12122/j.issn.1673-4254.2019.01.18.
8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验